The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
2004 · Pharmacogenetics · 444 citations
https://doi.org/10.1097/00008571-200403000-00002
M
Michel Mourad
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
208
Papers
5.0K
Citations
37
h-index
85
i10-index
Michel Mourad is an academic researcher from Agricultural Research Center. The author has contributed to research in topics: Renal Transplantation Outcomes and Treatments & Organ Transplantation Techniques and Outcomes & Pharmacological Effects and Toxicity Studies. The author has an h-index of 37, co-authored 177 publications.
ORCID: 0000-0002-0372-275XPapers by this author
worksOxygenated End-Hypothermic Machine Perfusion in Expanded Criteria Donor Kidney Transplant
2021 · JAMA Surgery · 67 citations
https://doi.org/10.1001/jamasurg.2021.0949
Genotype and Outcome After Kidney Transplantation in Alport Syndrome
2018 · Kidney International Reports · 40 citations
https://doi.org/10.1016/j.ekir.2018.01.008
A Simultaneous D‐Optimal Designed Study for Population Pharmacokinetic Analyses of Mycophenolic Acid and Tacrolimus Early After Renal Transplantation
2011 · The Journal of Clinical Pharmacology · 39 citations
https://doi.org/10.1177/0091270011423661
Basiliximab vs. No Induction Therapy in Kidney Transplant Recipients with a Low Immunological Risk Profile Receiving Tacrolimus/Mycophenolate/Steroids Maintenance Immunosuppression
2024 · Journal of Clinical Medicine · 2 citations
https://doi.org/10.3390/jcm13206151
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat